Last reviewed · How we verify

NCT05217147

An Investigation of Biomarker Candidate Molecules in Laryngeal Carcinoma

Completed Last updated 22 September 2023
What this trial tests

trial testing Obtaining blood samples in Larynx Cancer in 80 participants. Completed in 31 August 2021.

Timeline
1 May 2018
Primary endpoint
1 February 2020
31 August 2021

Quick facts

Lead sponsorHacettepe University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment80
Start date1 May 2018
Primary completion1 February 2020
Estimated completion31 August 2021
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Hacettepe University

Who can join

Eligibility, any sex, with Larynx Cancer or Larynx Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study was to determine serum levels of VEGF, sVEGFR1, VEGFR2, IGFBP-3, angiogenin and endoglin in patients with larynx squamous cell carcinoma; investigate their association with clinical parameters and determine their diagnostic and prognostic value.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Larynx Cancer

Currently open trials in the same condition.

Other Hacettepe University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05217147.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing